Singapore With Amgen having recently reacquired the sales rights to three of its drugs, the company’s GM in Singapore and Malaysia, Raphael Ho, explains the rationale behind Amgen’s recent entry in Singapore and his experience in setting up the affiliate, while also expounding upon the unique value of Amgen products in…
Merck Asanga Halangoda, Director of Life Science at Merck Philippines, discusses the company’s impressive recent market performance, the importance of innovation in maintaining product pipeline, and the bright future of the affiliate’s role in the company’s emerging market portfolio. As an introduction to our readers, could you please give us an…
Biotech Ronald Scott, CEO of Basilea, a biotech company that was spun out of Roche in 2000, talks about launching its first two products, Zevtera and Cresemba; the milestone agreement with the Biomedical Advanced Research and Development Authority (BARDA) to develop Zevtera for the US market; and about the company’s partnering…
Ireland Noel Heaney, general manager of BMS Biologics Ireland, provides an overview of BMS in Ireland, its exciting new USD 900 million biologics facility in Cruiserath, their innovative HR programs and his five-year-vision for BMS Biologics in Ireland. BMS has a strong heritage in Ireland dating back to 1964 when it…
Ireland Already the fifth-largest MedTech manufacturing hub in the world, Ireland is fast growing as an innovative center for the global industry, with several multinational R&D facilities in the country and a vibrant startup scene. IMDA Director Sinead Keogh discusses the changing regulatory and policy environment, how this is impacting the…
Medtech Fernando Oliveros, VP of Medtronic Mexico, explains how the global medical devices leader wants to leverage Covidien’s integration to improve health outcomes in Mexico. By taking advantage of an innovative product portfolio, the potential of their services portfolio and closely partnering with public stakeholders, Medtronic is ready to become a…
Hungary Hungary’s medicinal biotech companies are clustered in the country’s four major university towns: Budapest, Debrecen, Szeged and Pécs, with the majority basing themselves in the capital, Budapest. Click here to read more articles and interviews from Hungary
Pharma Singapore, though conscious of its limitations, has been able to leverage its key assets of location, infrastructure and local talent in order to become the business hub for the entire region, with pharma and biotech as key components in its success. Singapore is … an attractive investment destination, especially for the…
Pharma With nearly €4 billion of capital investment in large molecule manufacturing underway, Ireland’s strategy to become a premier destination for biologics FDI has proven to be successful, according to BioPharmaChem Ireland director Matt Moran. Yet, Ireland today is much more than a manufacturing hub, and is well on its way to…
Biotech The chairman of BioSingapore, Dr. Siew Hwa Ong, discusses the opportunities and challenges facing biotech SMEs in Singapore, government efforts to enhance the business environment for these SMEs, and facilitating more collaboration between companies as the most prominent pathway for future development. Could you please introduce yourself to our international…
Pharma The executive director of A*STAR’s Biomedical Research Council, Dr. Benjamin Seet highlights several remarkable milestones that the organization has been able to achieve since its inception, while underscoring how cultivating deep levels of expertise will carry Singapore’s biomedical sciences sector into its next phase of development. In a few words,…
Medtech France has a rich history in innovation, especially in the medical devices sector, but has not been able to produce a giant in the sector to compare with the global impact of Sanofi and Servier in pharmaceuticals. New models of public-private partnership however have the potential to change this. Medical devices is…
See our Cookie Privacy Policy Here